Delaware News

AG Jennings Secures over $96K Settlement Following HIV Drug Kickback Investigation

Department of Justice | Department of Justice Press Releases | Newsroom | Date Posted: Thursday, July 17, 2025


Navy blue background featuring the Delaware state seal in the center
Delaware Attorney General Kathy Jennings announced on July 16, 2025, that Delaware has joined with other states and the federal government to reach an agreement in principle with an HIV drug manufacturer that will return $96,571.13 to Delaware’s Medicaid program.
Gilead Sciences, Inc. (“Gilead”), a California-based pharmaceutical company, has agreed to settle allegations that the company paid kickbacks to providers to improperly promote its HIV drugs, Stribild, Genvoya, Complera, Odefsey, Descovy, and Biktarvv. The $96,571 being returned to Delaware Medicaid is part of Gilead’s settlement with a group of states and the federal government, totaling $202 million, of which $49 million will go to state Medicaid programs.
“Kickbacks incentivize improper billing to the Medicaid program, ultimately taking healthcare resources from those truly in need,” Attorney General Jennings said.  “The Delaware Department of Justice will continue leading the fight to protect our state’s healthcare programs from fraud.”
The settlement—which was handled on behalf of Delaware by AG Jennings’ Medicaid Fraud Control Unit—will resolve allegations that from January 2011 through November 2017, Gilead made payments, provided meals, and paid travel expenses to healthcare practitioners who spoke at or attended Gilead speaker events.  These payments and gifts induced the healthcare practitioners to prescribe the Gilead HIV Drugs in violation of the Anti-Kickback Statute, causing false claims for the Gilead HIV Drugs to be submitted to Medicaid in violation of the Delaware False Claims and Reporting Act.
This settlement arises from a whistleblower action originally filed in 2016 in the United States District Court for the Southern District of New York under the federal False Claims Act and various state false claims statutes.
The Delaware Department of Justice’s Medicaid Fraud Control Unit receives 75 percent of its funding from the U.S. Department of Health and Human Services under a grant award totaling $2,115,488.00 for Federal fiscal year (FFY) 2025.  The remaining 25 percent, totaling $705,162.00 for FFY 2025, is funded by the State of Delaware.
image_printPrint

Graphic that represents delaware news on a mobile phone

Keep up to date by receiving a daily digest email, around noon, of current news release posts from state agencies on news.delaware.gov.

Here you can subscribe to future news updates.

AG Jennings Secures over $96K Settlement Following HIV Drug Kickback Investigation

Department of Justice | Department of Justice Press Releases | Newsroom | Date Posted: Thursday, July 17, 2025


Navy blue background featuring the Delaware state seal in the center
Delaware Attorney General Kathy Jennings announced on July 16, 2025, that Delaware has joined with other states and the federal government to reach an agreement in principle with an HIV drug manufacturer that will return $96,571.13 to Delaware’s Medicaid program.
Gilead Sciences, Inc. (“Gilead”), a California-based pharmaceutical company, has agreed to settle allegations that the company paid kickbacks to providers to improperly promote its HIV drugs, Stribild, Genvoya, Complera, Odefsey, Descovy, and Biktarvv. The $96,571 being returned to Delaware Medicaid is part of Gilead’s settlement with a group of states and the federal government, totaling $202 million, of which $49 million will go to state Medicaid programs.
“Kickbacks incentivize improper billing to the Medicaid program, ultimately taking healthcare resources from those truly in need,” Attorney General Jennings said.  “The Delaware Department of Justice will continue leading the fight to protect our state’s healthcare programs from fraud.”
The settlement—which was handled on behalf of Delaware by AG Jennings’ Medicaid Fraud Control Unit—will resolve allegations that from January 2011 through November 2017, Gilead made payments, provided meals, and paid travel expenses to healthcare practitioners who spoke at or attended Gilead speaker events.  These payments and gifts induced the healthcare practitioners to prescribe the Gilead HIV Drugs in violation of the Anti-Kickback Statute, causing false claims for the Gilead HIV Drugs to be submitted to Medicaid in violation of the Delaware False Claims and Reporting Act.
This settlement arises from a whistleblower action originally filed in 2016 in the United States District Court for the Southern District of New York under the federal False Claims Act and various state false claims statutes.
The Delaware Department of Justice’s Medicaid Fraud Control Unit receives 75 percent of its funding from the U.S. Department of Health and Human Services under a grant award totaling $2,115,488.00 for Federal fiscal year (FFY) 2025.  The remaining 25 percent, totaling $705,162.00 for FFY 2025, is funded by the State of Delaware.
image_printPrint

Graphic that represents delaware news on a mobile phone

Keep up to date by receiving a daily digest email, around noon, of current news release posts from state agencies on news.delaware.gov.

Here you can subscribe to future news updates.